Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy with a low resection rate. Chemotherapy and radiotherapy (RT) are the main treatment approaches for patients with advanced pancreatic cancer, and neoadjuvant chemoradiotherapy is considered a promising strategy to increase the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Changchang, Zhu, Yahui, Kong, Weiwei, Yang, Ju, Zhu, Linxi, Wang, Lei, Tang, Min, Chen, Jun, Li, Qi, He, Jian, Li, Aimei, Qiu, Xin, Gu, Qing, Chen, Dongsheng, Meng, Fanyan, Liu, Baorui, Qiu, Yudong, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434272/
https://www.ncbi.nlm.nih.gov/pubmed/36059628
http://dx.doi.org/10.3389/fonc.2022.879661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434272/
https://www.ncbi.nlm.nih.gov/pubmed/36059628
http://dx.doi.org/10.3389/fonc.2022.879661

Ejemplares similares